The Effect of Anti-calcitonin Gene-related Peptide (CGRP) Receptor Antibodies on the Headache Inducing Properties of CGRP and Cilostazol in Migraine Patients

Inclusion Criteria:

• Patients with migraine with or without aura according to the InternationalClassification of Headache Disorders with a frequency of ≥4 migraine days per month

• 50-100 kg weight

• Participants of childbearing potential must use safe contraception (birth control) orbe sexually abstinent

Exclusion Criteria:

• Any other primary headache disorder according to the International Classification ofHeadache Disorders except for tension-type headache

• Any secondary headache disorder according to the International Classification ofHeadache Disorders

• Migraine attack during the preceding 48 hours on provocation day

• Headache during the preceding 24 hours on provocation day

• Treatment with monoclonal antibodies or participation in clinical trials withmonoclonal antibodies during the preceding year

• Daily consumption of any other drug/medication than oral contraception (birth control)

• Consumption of any other drug/medication later than four times the plasma half-time ofthe drug on provocation day except for oral contraception

• Pregnant or active breastfeeding participants

• Any cardiovascular diseases including cerebrovascular disorders

• Information in patient history or during physical examination indicating psychiatricdisorders or substance abuse

• Information in patient history or during physical examination that the screeningphysician deems relevant for participation in the study